Stockreport

Sangamo Therapeutics Announces Updated Phase 1/2 STAAR Study Data in Fabry Disease Showing Sustained Benefit and Differentiated Safety Profile [Yahoo! Finance]

Sangamo Therapeutics, Inc.  (SGMO) 
Last sangamo therapeutics, inc. earnings: 2/28 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: investor.sangamo.com
PDF All 12 patients withdrawn from enzyme replacement therapy (ERT) remain off ERT, with sustained elevated a-Gal A activity observed for up to 19 months as of the data cut [Read more]